BAY 59-8862 in Treating Patients With Advanced Kidney Cancer

ClinicalTrials.gov ID: NCT00039169

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00039169. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced kidney cancer.

Study identification

NCT ID: NCT00039169
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Theradex; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Kidney Cancer

Interventions

ortataxel Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2001 (Type not available)
Primary completion: Not listed
Completion: Not listed
Last update posted: Jul 24, 2008

Started 2001

United States locations

U.S. sites: 11
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
Scripps Clinic	La Jolla	California	92037	—
Medical Consultants	Muncie	Indiana	47303	—
Ochsner Clinic	New Orleans	Louisiana	70121	—
Marlene & Stewart Greenebaum Cancer Center, University of Maryland	Baltimore	Maryland	21201	—
206 Research Associates	Greenbelt	Maryland	20770	—
St. Louis University Health Sciences Center	St Louis	Missouri	63110-0250	—
Billings Oncology Associates	Billings	Montana	59101	—
Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
State University of New York - Upstate Medical University	Syracuse	New York	13210	—
Huntsman Cancer Institute	Salt Lake City	Utah	84112	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00039169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 24, 2008 · Synced Nov 12, 2026